Codeine in Mechanically Ventilated Neonates

The recruitment status of this study is unknown because the information has not been verified recently.
Verified February 2012 by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).
Recruitment status was  Recruiting
Sponsor:
Information provided by (Responsible Party):
Jacob Aranda, State University of New York - Downstate Medical Center
ClinicalTrials.gov Identifier:
NCT01322204
First received: March 22, 2011
Last updated: February 7, 2012
Last verified: February 2012

March 22, 2011
February 7, 2012
August 2008
July 2012   (final data collection date for primary outcome measure)
The rate and extent of absorption of oral codeine, the ratios of the observed concentration of each metabolite to the observed concentration of parent drug and the formation and clearances of the metabolites. [ Time Frame: 2 hours ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01322204 on ClinicalTrials.gov Archive Site
Secondary outcomes include the additional PK parameters elimination half life, area under the curve and mean residence time. [ Time Frame: 2 hours ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Codeine in Mechanically Ventilated Neonates
Absorption and Metabolism of Oral Codeine in Mechanically Ventilated Neonates

The purpose of this study is to determine the absorption and bioavailability of codeine in relation to postnatal (PNA) and postconceptional (PCA) age; determine the parent drug (codeine), its active metabolites, their formation rates and their ratios in relation with PCA and PNA; and identify relevant genetic polymorphisms of opioid metabolism in the study population and their potential relationship to the biodisposition and pharmacodynamic effects of codeine. The study population is intubated and mechanically ventilated infants equal to or greater than 26 weeks gestational age at birth and less than 4 weeks postnatal age.

This proposal has its origins in a larger initiative to elucidate the pharmacological basis for the interindividual differences observed in opioid responsiveness. Gaps in our knowledge related to opioid disposition in newborns need to be addressed to complete the design of the required overarching initiative in which age could be treated as a continuous variable within a context of PK, PD and PG determinants.This proposal is designed to generate preliminary data that addresses two issues. First, can newborns absorb enterally administered codeine and is this ability determined by PCA or PNA age? The second relates to the ability of newborn infants to catalyze those reactions required to metabolically activate both codeine and morphine. The latter will also be evaluated within the context of PCA versus PNA age.

These data will not only fill an information gap that must be addressed before the larger initiative moves forward, but they also provide a platform for serious study of the ontogeny of certain pharmacokinetic processes that may prove critical to our understanding of newborn drug disposition. In this way, codeine can provide important insights concerning the ontogeny of drug disposition and permit the determination of the relative importance of PCA versus PNA ages to the functional expression of these processes.

Interventional
Phase 1
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Mechanically Ventilated Neonates,
  • Painful Procedures in Newborns
Drug: Codeine
One single oral dose of 1 mg/kg of codeine
Experimental: 1
Neonates 0-30 days, no more than 2,000 grams, receiving mechanical ventilation.
Intervention: Drug: Codeine
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
64
Not Provided
July 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Neonates ≥ 26 weeks PCA receiving mechanical ventilation and painful procedure will be eligible for participation in the study
  • Subject's parent/legal guardian must give written informed consent prior to study participation
  • Subject is receiving opioid analgesia therapy based on caregiver determination. The ideal patient will not be receiving morphine.
  • Must be able to receive an enteral dose of codeine.

Exclusion Criteria:

  • Known hypersensitivity to morphine, fentanyl, or codeine
  • Patients with ALT concentrations >2x upper limit of normal for age or clinical evidence of hepatic failure
  • Patients with serum creatinine concentrations >2x upper limit of normal for age or clinical evidence of renal failure
  • Patients who are NPO
  • Babies born to maternal drug abuse.
  • Total serum bilirubin level of > 10 mg/dl or 170 umol/L.
Both
up to 30 Days
No
Contact: Jacob V Aranda, MD, PhD 718-270-3092 jaranda@downstate.edu
Contact: Jeffrey L Blumer, MD, PhD 216-844-3310 jeffrey.blumer@uhhospitals.org
United States
 
NCT01322204
10922
Yes
Jacob Aranda, State University of New York - Downstate Medical Center
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Not Provided
Principal Investigator: Jacob V Aranda, MD, PhD State University of New York Downstate
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
February 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP